PT2766380T - Compostos de 19-nor pregnano 3,3-dissubstituídos, composições e seus usos - Google Patents
Compostos de 19-nor pregnano 3,3-dissubstituídos, composições e seus usosInfo
- Publication number
- PT2766380T PT2766380T PT12781534T PT12781534T PT2766380T PT 2766380 T PT2766380 T PT 2766380T PT 12781534 T PT12781534 T PT 12781534T PT 12781534 T PT12781534 T PT 12781534T PT 2766380 T PT2766380 T PT 2766380T
- Authority
- PT
- Portugal
- Prior art keywords
- disubstituted
- compositions
- pregnane compounds
- pregnane
- compounds
- Prior art date
Links
- ALSXNTIVNJBNQE-ZWONNITHSA-N (8r,9r,10s,13r,14s,17s)-17-ethyl-13-methyl-1,2,3,4,5,6,7,8,9,10,11,12,14,15,16,17-hexadecahydrocyclopenta[a]phenanthrene Chemical class C1CC2CCCC[C@@H]2[C@@H]2[C@@H]1[C@@H]1CC[C@H](CC)[C@@]1(C)CC2 ALSXNTIVNJBNQE-ZWONNITHSA-N 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J43/00—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
- C07J43/003—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton not condensed
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J31/00—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring
- C07J31/006—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring not covered by C07J31/003
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J5/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond
- C07J5/0007—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond not substituted in position 17 alfa
- C07J5/0015—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond not substituted in position 17 alfa not substituted in position 16
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J7/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
- C07J7/0005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21
- C07J7/001—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group
- C07J7/0015—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group not substituted in position 17 alfa
- C07J7/002—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group not substituted in position 17 alfa not substituted in position 16
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J7/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
- C07J7/008—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms substituted in position 21
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J7/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
- C07J7/008—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms substituted in position 21
- C07J7/0085—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms substituted in position 21 by an halogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
- C07J9/005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane containing a carboxylic function directly attached or attached by a chain containing only carbon atoms to the cyclopenta[a]hydrophenanthrene skeleton
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Biomedical Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurosurgery (AREA)
- Pharmacology & Pharmacy (AREA)
- Neurology (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Psychology (AREA)
- Cardiology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Anesthesiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
- Fats And Perfumes (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161547291P | 2011-10-14 | 2011-10-14 | |
| US201261698204P | 2012-09-07 | 2012-09-07 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PT2766380T true PT2766380T (pt) | 2019-07-29 |
Family
ID=47143295
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PT12781534T PT2766380T (pt) | 2011-10-14 | 2012-10-12 | Compostos de 19-nor pregnano 3,3-dissubstituídos, composições e seus usos |
Country Status (9)
| Country | Link |
|---|---|
| US (5) | US20150291654A1 (cg-RX-API-DMAC7.html) |
| EP (2) | EP3572417B1 (cg-RX-API-DMAC7.html) |
| JP (5) | JP2014528485A (cg-RX-API-DMAC7.html) |
| CN (4) | CN104136452A (cg-RX-API-DMAC7.html) |
| AU (5) | AU2012323888A1 (cg-RX-API-DMAC7.html) |
| CA (2) | CA2852057C (cg-RX-API-DMAC7.html) |
| ES (1) | ES2738526T3 (cg-RX-API-DMAC7.html) |
| PT (1) | PT2766380T (cg-RX-API-DMAC7.html) |
| WO (1) | WO2013056181A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (62)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EA017290B1 (ru) | 2005-11-28 | 2012-11-30 | Домейн Раша Инвестментс Лимитед | Композиции на основе ганаксолона |
| SMT202300232T1 (it) | 2011-09-08 | 2023-09-06 | Sage Therapeutics Inc | Steroidi neuroattivi, composizioni e relativi usi |
| JP2014528485A (ja) | 2011-10-14 | 2014-10-27 | セージ セラピューティクス， インコーポレイテッド | ３，３−二置換１９−ノルプレグナン化合物およびその使用 |
| BR112014018110B1 (pt) | 2012-01-23 | 2022-06-07 | Sage Therapeutics, Inc | Composições farmacêutica aquosas formuladas para administração parenteral e uso de alopregnanolona e sulfobutiléter-b-ciclodextrina |
| IL294306B2 (en) | 2012-08-21 | 2024-01-01 | Sage Therapeutics Inc | Methods of treating epilepsy or status epilepticus |
| US20150313915A1 (en) | 2012-11-30 | 2015-11-05 | The Regents Of The University Of California | Anticonvulsant activity of steroids |
| AU2014243773B2 (en) | 2013-03-13 | 2018-12-13 | Sage Therapeutics, Inc. | Neuroactive steroids and methods of use thereof |
| WO2014169831A1 (en) | 2013-04-17 | 2014-10-23 | Sage Therapeutics, Inc. | 19-nor c3,3-disubstituted c21-c-bound heteroaryl steroids and methods of use thereof |
| WO2014169836A1 (en) * | 2013-04-17 | 2014-10-23 | Sage Therapeutics, Inc. | 19-nor neuroactive steroids and methods of use thereof |
| RS58297B1 (sr) | 2013-04-17 | 2019-03-29 | Sage Therapeutics Inc | 19-nor c3,3-disupstituisani c21-n-pirazolil steroidi i postupci za njihovu upotrebu |
| AU2014256228C1 (en) | 2013-04-17 | 2017-09-14 | Sage Therapeutics, Inc. | 19-nor neuroactive steroids and methods of use thereof |
| BR112016000975B1 (pt) | 2013-07-19 | 2020-10-06 | Sage Therapeutics, Inc. | Compostos esteróides neuroativos e composições compreendendo os mesmos |
| RS61370B1 (sr) | 2013-08-23 | 2021-02-26 | Sage Therapeutics Inc | Neuroaktivni steroidi, njihove kompozicije i upotreba |
| TW201625661A (zh) * | 2014-05-29 | 2016-07-16 | 賽吉醫療公司 | 神經活性類固醇，其組合物及其用途 |
| US10246482B2 (en) | 2014-06-18 | 2019-04-02 | Sage Therapeutics, Inc. | Neuroactive steroids, compositions, and uses thereof |
| WO2015195967A1 (en) * | 2014-06-18 | 2015-12-23 | Sage Therapeutics, Inc. | Oxysterols and methods of use thereof |
| JOP20200195A1 (ar) | 2014-09-08 | 2017-06-16 | Sage Therapeutics Inc | سترويدات وتركيبات نشطة عصبياً، واستخداماتها |
| KR20170103745A (ko) * | 2014-09-17 | 2017-09-13 | 프리바쿠스, 인코포레이티드 | C-20 스테로이드 화합물, 뇌진탕을 포함하는 외상성 뇌손상(tbi)을 치료하기 위한 조성물 및 이의 용도 |
| DK3206493T3 (da) * | 2014-10-16 | 2020-08-10 | Sage Therapeutics Inc | Sammensætninger og fremgangsmåder til behandling af cns-forstyrrelser |
| CN118344424A (zh) | 2014-10-16 | 2024-07-16 | 萨奇治疗股份有限公司 | 靶向cns障碍的组合物和方法 |
| SI3224269T1 (sl) | 2014-11-27 | 2020-10-30 | Sage Therapeutics, Inc. | Sestavki in metode za zdravljenje CNS motenj |
| ES2857082T3 (es) | 2015-01-26 | 2021-09-28 | Sage Therapeutics Inc | Composiciones y métodos para el tratamiento de trastornos del SNC |
| ES2935476T3 (es) | 2015-02-20 | 2023-03-07 | Sage Therapeutics Inc | Esteroides neuroactivos, composiciones y usos de los mismos |
| EP3280420B1 (en) * | 2015-04-10 | 2024-03-27 | Sage Therapeutics, Inc. | Compositions and methods for treating cns disorders |
| MA45276A (fr) | 2015-06-18 | 2018-04-25 | Sage Therapeutics Inc | Solutions de stéroïdes neuroactifs et leurs méthodes d'utilisation |
| AU2016289971C1 (en) | 2015-07-06 | 2022-12-08 | Sage Therapeutics, Inc. | Oxysterols and methods of use thereof |
| BR122021005552B1 (pt) | 2015-07-06 | 2024-01-02 | Sage Therapeutics, Inc | Compostos oxiesteróis, seus usos e composição farmacêutica |
| WO2017007832A1 (en) * | 2015-07-06 | 2017-01-12 | Sage Therapeutics, Inc. | Oxysterols and methods of use thereof |
| US10780099B2 (en) | 2015-10-16 | 2020-09-22 | Marinus Pharmaceuticals, Inc. | Injectable neurosteroid formulations containing nanoparticles |
| US20200306265A1 (en) | 2016-03-08 | 2020-10-01 | Sage Therapeutics, Inc. | Neuroactive steroids, compositions, and uses thereof |
| EP3436022B1 (en) | 2016-04-01 | 2022-03-09 | Sage Therapeutics, Inc. | Oxysterols and methods of use thereof |
| US10752653B2 (en) | 2016-05-06 | 2020-08-25 | Sage Therapeutics, Inc. | Oxysterols and methods of use thereof |
| PT3481846T (pt) | 2016-07-07 | 2021-08-13 | Sage Therapeutics Inc | 24-hidroxiesteroides 11-substituídos para utilização no tratamento de afeções relacionadas com nmda |
| AU2017297375B2 (en) | 2016-07-11 | 2022-09-15 | Sage Therapeutics, Inc. | C17, C20, and C21 substituted neuroactive steroids and their methods of use |
| WO2018013615A1 (en) | 2016-07-11 | 2018-01-18 | Sage Therapeutics, Inc. | C7, c12, and c16 substituted neuroactive steroids and their methods of use |
| KR20230050474A (ko) | 2016-08-11 | 2023-04-14 | 오비드 테라퓨틱스 인크. | 간질 장애의 치료를 위한 방법 및 조성물 |
| MA46042A (fr) | 2016-08-23 | 2019-07-03 | Sage Therapeutics Inc | Stéroïde c21-n-pyrazolyle 3-disubstitué en 19-nor c3 cristallin |
| US10391105B2 (en) | 2016-09-09 | 2019-08-27 | Marinus Pharmaceuticals Inc. | Methods of treating certain depressive disorders and delirium tremens |
| WO2018064649A1 (en) | 2016-09-30 | 2018-04-05 | Sage Therapeutics, Inc. | C7 substituted oxysterols and methods as nmda modulators |
| RU2019115112A (ru) * | 2016-10-18 | 2020-11-24 | Сейдж Терапьютикс, Инк. | Оксистеролы и способы их применения |
| RU2019115113A (ru) | 2016-10-18 | 2020-11-24 | Сейдж Терапьютикс, Инк. | Оксистеролы и способы их применения |
| WO2019075362A1 (en) * | 2017-10-12 | 2019-04-18 | Sage Therapeutics, Inc. | METHOD OF TREATING CENTRAL NERVOUS SYSTEM DISORDERS WITH NEUROSTEROIDS AND GABAERGIC COMPOUNDS |
| EP4484440A3 (en) | 2017-12-08 | 2025-03-26 | Sage Therapeutics, Inc. | Deuterated 21 -[4-cyano-pyrazol-1 -yl]-19-nor-pregan-3. alpha-ol-20-one derivatives for treating cns disorders |
| CA3086299A1 (en) | 2017-12-22 | 2019-06-27 | Sage Therapeutics, Inc. | Compositions and methods for treating cns disorders |
| MX2020008182A (es) * | 2018-02-11 | 2020-09-22 | Jiangsu Hansoh Pharmaceutical Group Co Ltd | Reguladores de derivados esteroides, metodo para prepararlos y usos de los mismos. |
| CN110709409B (zh) * | 2018-02-11 | 2022-05-31 | 江苏豪森药业集团有限公司 | 一种甾族类衍生物调节剂及其制备方法和应用 |
| IL312610A (en) | 2018-12-05 | 2024-07-01 | Sage Therapeutics Inc | Neuroactive steroids and methods of using them |
| US11266662B2 (en) | 2018-12-07 | 2022-03-08 | Marinus Pharmaceuticals, Inc. | Ganaxolone for use in prophylaxis and treatment of postpartum depression |
| WO2020132504A1 (en) | 2018-12-21 | 2020-06-25 | Sage Therapeutics, Inc. | 3.alpha.-hydroxy-17.beta.-amide neuroactive steroids and compositions thereof |
| BR112021024033A2 (pt) | 2019-05-31 | 2022-02-08 | Sage Therapeutics Inc | Esteroides neuroativos e suas composições |
| MX2022001553A (es) | 2019-08-05 | 2022-04-18 | Marinus Pharmaceuticals Inc | Ganaxolona para su uso en el tratamiento del estado epileptico. |
| KR102890254B1 (ko) * | 2019-08-07 | 2025-11-24 | 상하이 한서 바이오메디컬 컴퍼니 리미티드 | 스테로이드 유도체 조절제의 염 및 결정형 |
| US10857163B1 (en) | 2019-09-30 | 2020-12-08 | Athenen Therapeutics, Inc. | Compositions that preferentially potentiate subtypes of GABAA receptors and methods of use thereof |
| US20210188897A1 (en) * | 2019-12-05 | 2021-06-24 | Sparx Therapeutics, Inc. | Neuroactive steroids and compositions and methods thereof |
| IL293525A (en) | 2019-12-06 | 2022-08-01 | Marinus Pharmaceuticals Inc | Ganaxolone for use in the treatment of multiple sclerosis complex |
| EP4110345A4 (en) * | 2020-02-27 | 2024-05-15 | Brii Biosciences, Inc. | PRODRUGS OF NEUROACTIVE STEROIDS |
| US20230414636A1 (en) | 2020-03-25 | 2023-12-28 | Sage Therapeutics, Inc. | Use of gabaa modulators for treatment of respiratory conditions |
| BR112024001518A2 (pt) | 2021-07-28 | 2024-04-30 | Sage Therapeutics Inc | Formas cristalinas de um esteroide neuroativo |
| US20250368678A1 (en) * | 2022-06-09 | 2025-12-04 | Shandong Luye Pharmaceutical Co., Ltd. | 19-nor-c3,3-disubstituted c21-azacyclo-substituted steroid and method for using same |
| WO2024059608A1 (en) | 2022-09-15 | 2024-03-21 | Sage Therapeutics, Inc. | Deuterated neuroactive steroids |
| KR20250162825A (ko) | 2023-03-14 | 2025-11-19 | 쿠리아 스페인, 에스.에이.유. | 3알파-하이드록시-3베타-알킬 스테로이드의 제조를 위한 방법 및 중간체 |
| WO2025119319A1 (zh) * | 2023-12-08 | 2025-06-12 | 山东绿叶制药有限公司 | 一种gabaa受体调节剂的晶型及其制备方法和应用 |
Family Cites Families (97)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR1994E (fr) | 1902-11-20 | 1903-11-24 | Jules Bernard | Dispositif de suspension élastique amortisseur de chocs pour chassis, caisses de véhicules, sièges et sommiers élastiques |
| US2856415A (en) | 1957-11-13 | 1958-10-14 | Searle & Co | 3,19-dihydroxy-5-androstene derivatives |
| US3206459A (en) | 1962-10-19 | 1965-09-14 | Syntex Corp | 10alpha-pregnan-19-ol derivatives |
| US3169134A (en) | 1963-03-21 | 1965-02-09 | Searle & Co | 2, 3-oxygenated-17alpha-methyl-5alpha-androstan-17beta-ols |
| BE754111A (fr) | 1969-07-29 | 1971-01-29 | Upjohn Co | Nouveaux 7alpha- et 7beta-methyl-3alpha,5alpha- cycloandrostanes et composes analogues 19-nor et leur procede de preparation |
| GB1380246A (en) | 1970-12-17 | 1975-01-08 | Glaxo Lab Ltd | 3alpha-hydroxy-androstanes and esters thereof |
| US3943124A (en) | 1970-12-17 | 1976-03-09 | Gordon Hanley Phillipps | Chemical compounds |
| US3983111A (en) | 1972-05-05 | 1976-09-28 | Glaxo Laboratories Limited | Steroidal anaesthetics of the pregnane and 19-norpregnane series |
| GB1430942A (en) | 1972-05-05 | 1976-04-07 | Glaxo Lab Ltd | 21-substituted 3alpha-hydroxy pregnanes |
| GB1436324A (en) | 1972-05-12 | 1976-05-19 | Glaxo Lab Ltd | Anaesthetic 3alpha-hydroxy pregnanes |
| US4071625A (en) | 1974-05-13 | 1978-01-31 | Richardson-Merrell Inc. | 19-Oxygenated-5α-androstanes for the enhancement of libido |
| DE2526373C2 (de) | 1975-06-11 | 1983-11-10 | Schering AG, 1000 Berlin und 4709 Bergkamen | Verfahren zur Herstellung von Δ↑9↑↑(↑↑1↑↑1↑↑)↑-5α-20-Ketosteroiden |
| GB1570394A (en) | 1976-01-06 | 1980-07-02 | Glaxo Lab Ltd | 11-acyloxy-3-hydroxy steroids |
| US4192871A (en) * | 1976-01-06 | 1980-03-11 | Glaxo Laboratories Limited | Chemical compounds |
| GB1581234A (en) | 1976-04-05 | 1980-12-10 | Glaxo Operations Ltd | 11a - amino - 3a - hydroxysteroids |
| DE2632677A1 (de) | 1976-07-16 | 1978-01-26 | Schering Ag | Verfahren zur herstellung von androstan-17-on-derivaten und deren verwendung |
| US4389345A (en) | 1981-10-09 | 1983-06-21 | G.D. Searle & Co. | 3-Oxoestra-17-acetonitrile and unsaturated analogs |
| US4495102A (en) | 1982-09-03 | 1985-01-22 | G. D. Searle & Co. | Aminoalkyl steroids |
| AU609927B2 (en) * | 1987-08-25 | 1991-05-09 | Kelvin W. Gee | Compositions and methods for alleviating stress, anxiety and seizure activity |
| US5232917A (en) | 1987-08-25 | 1993-08-03 | University Of Southern California | Methods, compositions, and compounds for allosteric modulation of the GABA receptor by members of the androstane and pregnane series |
| US5120723A (en) | 1987-08-25 | 1992-06-09 | University Of Southern California | Method, compositions, and compounds for modulating brain excitability |
| US5319115A (en) | 1987-08-25 | 1994-06-07 | Cocensys Inc. | Method for making 3α-hydroxy, 3β-substituted-pregnanes |
| US5376645A (en) | 1990-01-23 | 1994-12-27 | University Of Kansas | Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof |
| EP0603312A4 (en) | 1991-09-13 | 1995-06-07 | Cocensys Inc | NEW GABA A RECEPTOR WITH STEROID BINDING POINTS. |
| DE4232681C2 (de) | 1992-09-29 | 1994-11-24 | Sigma Tau Ind Farmaceuti | 17-Phenyl- und 17-Furyl-14beta,5alpha-androstan- und androsten- Derivate, Verfahren zu deren Herstellung und diese enthaltende pharmazeutische Zusammensetzung |
| JP4008024B2 (ja) * | 1993-05-24 | 2007-11-14 | パーデュー、ファーマ、リミテッド、パートナーシップ | Ｇａｂａａレセプター複合体と相互作用させるための化合物 |
| CZ300694A3 (en) | 1993-12-02 | 1996-05-15 | Akzo Nobel Nv | Substituted 2beta-morpholinandrostane derivatives, process of their preparation, their use for preparing pharmaceutical preparations and pharmaceutical compositions containing thereof |
| EP0656365B1 (en) | 1993-12-02 | 1997-04-09 | Akzo Nobel N.V. | Substituted 2beta-morpholinoandrostane derivatives |
| DK1038880T3 (da) | 1994-02-14 | 2008-03-03 | Euro Celtique Sa | Androstaner og pregnaner til allosterisk modulering af GABA-receptor |
| US5939545A (en) * | 1994-02-14 | 1999-08-17 | Cocensys, Inc. | Method, compositions, and compounds for allosteric modulation of the gaba receptor by members of the androstane and pregnane series |
| WO1996003421A1 (en) | 1994-07-21 | 1996-02-08 | Pharmacia & Upjohn Company | Neurologically active aminosteroids |
| PT808325E (pt) * | 1994-11-23 | 2001-06-29 | Cocensys Inc | Series de androstanos e pregnanos para modulacao alosterica do receptor de gaba |
| KR19990022323A (ko) | 1995-06-06 | 1999-03-25 | 씨. 랜 낸시 | 안드로스탄 및 프레그난 시리즈의 신경활성 스테로이드 |
| WO1998005337A1 (en) * | 1996-08-01 | 1998-02-12 | Cocensys, Inc. | Use of gaba and nmda receptor ligands for the treatment of migraine headache |
| US5994334A (en) | 1997-02-05 | 1999-11-30 | University Of Maryland | Androgen synthesis inhibitors |
| US5935545A (en) | 1997-07-11 | 1999-08-10 | E. I. Du Pont De Nemours And Company | Process for producing an aqueous solution comprising ferric chloride |
| WO2000066614A1 (en) * | 1999-04-29 | 2000-11-09 | Purdue Pharma Ltd. | 3α-HYDROXY-3β METHOXYMETHYL-21-HETEROCYCLE SUBSTITUTED STEROIDS WITH ANESTHETIC ACTIVITY |
| US7018406B2 (en) | 1999-11-17 | 2006-03-28 | Corevalve Sa | Prosthetic valve for transluminal delivery |
| US6717002B2 (en) | 2000-02-18 | 2004-04-06 | Taiho Pharmaceutical Co., Ltd. | Method of producing steroid derivatives |
| US6855836B2 (en) | 2000-10-26 | 2005-02-15 | Jenapharm Gmbh & Co. Kg | 17-Methylene steroids, process for their production and pharmaceutical compositions that contain these compounds |
| ATE361310T1 (de) | 2000-11-03 | 2007-05-15 | Univ Washington | Östronderivate mit zellschützender wirkung |
| GR1003861B (el) | 2000-12-29 | 2002-04-11 | Νεα νευροστεροειδη που αλληλεπιδρουν με τον υποδοχεα gabaa. | |
| BRPI0408703A (pt) | 2003-03-24 | 2006-03-07 | Sterix Ltd | derivados de estrogênio como inibidores da esteróide sulfatase |
| EP1626980A4 (en) | 2003-05-29 | 2007-07-04 | Univ Washington | NEUROACTIVE 13,24-CYCLO-18,21-DINORCHOLANES AND STRUCTURELY RELATED PENTACYCLIC STEROIDS |
| EP1689767A1 (en) | 2003-11-24 | 2006-08-16 | Merck & Co., Inc. | Estrogen receptor modulators |
| WO2005105822A2 (en) | 2004-04-23 | 2005-11-10 | Euro-Celtique S.A. | 3-alpha-hydroxy 21-n- heteroaryl-pregnane derivatives for modulation of brain excitability and a process for the production thereof |
| US8604011B2 (en) | 2004-09-27 | 2013-12-10 | The Regents Of The University Of California | Therapy for treatment of chronic degenerative brain diseases and nervous system injury |
| AU2005330504B2 (en) | 2004-09-29 | 2010-10-28 | Harbor Biosciences, Inc. | Steroid analogs and characterization and treatment methods |
| UA94909C2 (ru) | 2005-06-09 | 2011-06-25 | Евро-Селтик С.А. | Фармацевтическая композиция нейроактивного стероида и ее применение |
| US20090203658A1 (en) | 2007-01-08 | 2009-08-13 | Duke University | Neuroactive steroid compositions and methods of use therefor |
| DE102007027636A1 (de) | 2007-06-12 | 2008-12-18 | Bayer Schering Pharma Aktiengesellschaft | 17ß-Cyano-18a-homo-19-nor-androst-4-en-Derivat, dessen Verwendung und das Derivat enthaltende Arzneimittel |
| AU2008265898B2 (en) | 2007-06-15 | 2013-11-28 | Research Triangle Institute | Androstane and pregnane steroids with potent allosteric GABA receptor chloride ionophore modulating properties |
| GB0711948D0 (en) | 2007-06-20 | 2007-08-01 | Bionature E A Ltd | Neurosteriod compounds |
| CN101412742B (zh) | 2007-10-19 | 2013-07-31 | 天津金耀集团有限公司 | 一种抑制血管新生的硝酸酯药物 |
| US20090264443A1 (en) | 2008-04-18 | 2009-10-22 | David Helton | Treatment of organophosphate exposure with tetrahydroindolone arylpiperazine compounds |
| CN101624414B (zh) | 2008-07-07 | 2013-02-13 | 天津金耀集团有限公司 | 一种抑制血管新生的硝酸酯药物 |
| CZ2008434A3 (cs) | 2008-07-10 | 2009-12-09 | Ústav organické chemie a biochemie Akademie ved CR, v. v. i. | Pregnanové anionické slouceniny, zpusob jejich výroby a jejich použití |
| WO2011079047A1 (en) | 2009-12-23 | 2011-06-30 | Drugtech Corporation | Methods for reducing the occurrence of preterm delivery and other pregnancy-related conditions |
| US20130303500A1 (en) | 2010-07-30 | 2013-11-14 | Medexis S.A. | Compounds and methods for treating neoplasia |
| CN103347525A (zh) | 2010-12-15 | 2013-10-09 | 哈博生物科学公司 | 制备3α-氧取代的甾族化合物的方法及化合物 |
| WO2012109752A1 (en) | 2011-02-15 | 2012-08-23 | Socpra Sciences Et Génie, S.E.C. | Steroid alkaloids and uses thereof as antimicrobial agents against electron transport-deficient microbes and as potentiators for antimicrobial agents against pathogenic bacteria |
| CZ303443B6 (cs) | 2011-02-15 | 2012-09-12 | Ústav organické chemie a biochemie Akademie ved CR, v.v.i. | Deriváty pregnanolonu substituované v poloze 3alfa kationickou skupinou, zpusob jejich výroby, jejich použití a prostredek je obsahující |
| WO2012116290A2 (en) | 2011-02-25 | 2012-08-30 | Washington University | Neuroactive 17(20)-z-vinylcyano-substituted steroids, prodrugs thereof, and methods of treatment using same |
| EP3296405B1 (en) | 2011-03-23 | 2019-10-09 | Etsuro Ito | Method and kit for super-high-sensitivity measurement of protein and nucleic acid, and novel enzyme substrate |
| JP2014521662A (ja) | 2011-07-29 | 2014-08-28 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | ＧＡＢＡＡ受容体のモジュレーターとしての新規な１７β−ヘテロアリール置換ステロイド |
| SMT202300232T1 (it) | 2011-09-08 | 2023-09-06 | Sage Therapeutics Inc | Steroidi neuroattivi, composizioni e relativi usi |
| JP2014528485A (ja) | 2011-10-14 | 2014-10-27 | セージ セラピューティクス， インコーポレイテッド | ３，３−二置換１９−ノルプレグナン化合物およびその使用 |
| US20150175651A1 (en) | 2012-06-15 | 2015-06-25 | Sage Therapeutics, Inc. | Neuroactive steroids, compositions, and uses thereof |
| US20140050789A1 (en) | 2012-08-13 | 2014-02-20 | The Regents Of The University Of California | Mitigation of epileptic seizures by combination therapy using benzodiazepines and neurosteroids |
| WO2014058736A1 (en) | 2012-10-08 | 2014-04-17 | Washington University | Neuroactive 19-alkoxy-17(20)-z-vinylcyano-substituted steroids, prodrugs thereof, and methods of treatment using same |
| US9757391B2 (en) | 2012-11-09 | 2017-09-12 | Goodchild Investments Pty Ltd | Neuroactive steroids and their use to facilitate neuroprotection |
| JP6542127B2 (ja) | 2012-12-18 | 2019-07-10 | ワシントン・ユニバーシティＷａｓｈｉｎｇｔｏｎ Ｕｎｉｖｅｒｓｉｔｙ | 向神経活性１９−アルコキシ−１７−置換ステロイド、そのプロドラッグおよびそれを使用する処置方法 |
| US8939545B2 (en) | 2012-12-20 | 2015-01-27 | Eastman Kodak Company | Inkjet printing with managed airflow for condensation control |
| US9562026B2 (en) | 2013-03-14 | 2017-02-07 | Washington University | Neuroactive substituted cyclopent[a]anthracenes as modulators for GABA type-A receptors |
| RS58297B1 (sr) | 2013-04-17 | 2019-03-29 | Sage Therapeutics Inc | 19-nor c3,3-disupstituisani c21-n-pirazolil steroidi i postupci za njihovu upotrebu |
| WO2014169836A1 (en) | 2013-04-17 | 2014-10-23 | Sage Therapeutics, Inc. | 19-nor neuroactive steroids and methods of use thereof |
| AU2014256228C1 (en) | 2013-04-17 | 2017-09-14 | Sage Therapeutics, Inc. | 19-nor neuroactive steroids and methods of use thereof |
| WO2014169831A1 (en) | 2013-04-17 | 2014-10-23 | Sage Therapeutics, Inc. | 19-nor c3,3-disubstituted c21-c-bound heteroaryl steroids and methods of use thereof |
| BR112016000975B1 (pt) | 2013-07-19 | 2020-10-06 | Sage Therapeutics, Inc. | Compostos esteróides neuroativos e composições compreendendo os mesmos |
| RS61370B1 (sr) | 2013-08-23 | 2021-02-26 | Sage Therapeutics Inc | Neuroaktivni steroidi, njihove kompozicije i upotreba |
| TW201625661A (zh) | 2014-05-29 | 2016-07-16 | 賽吉醫療公司 | 神經活性類固醇，其組合物及其用途 |
| US10246482B2 (en) | 2014-06-18 | 2019-04-02 | Sage Therapeutics, Inc. | Neuroactive steroids, compositions, and uses thereof |
| DK3206493T3 (da) | 2014-10-16 | 2020-08-10 | Sage Therapeutics Inc | Sammensætninger og fremgangsmåder til behandling af cns-forstyrrelser |
| CN118344424A (zh) | 2014-10-16 | 2024-07-16 | 萨奇治疗股份有限公司 | 靶向cns障碍的组合物和方法 |
| SI3224269T1 (sl) | 2014-11-27 | 2020-10-30 | Sage Therapeutics, Inc. | Sestavki in metode za zdravljenje CNS motenj |
| ES2857082T3 (es) | 2015-01-26 | 2021-09-28 | Sage Therapeutics Inc | Composiciones y métodos para el tratamiento de trastornos del SNC |
| ES2935476T3 (es) | 2015-02-20 | 2023-03-07 | Sage Therapeutics Inc | Esteroides neuroactivos, composiciones y usos de los mismos |
| UY36741A (es) | 2015-06-21 | 2016-12-30 | Prevacus Inc | Compuesto de esteroide c-20, sus composiciones y usos para tratar la lesión cerebral traumática (tbi), que incluye las conmociones cerebrales |
| CA2998134A1 (en) | 2015-09-08 | 2017-03-16 | Viewpoint Therapeutics, Inc. | Compounds and formulations for treating ophthalmic diseases |
| US10780099B2 (en) | 2015-10-16 | 2020-09-22 | Marinus Pharmaceuticals, Inc. | Injectable neurosteroid formulations containing nanoparticles |
| EP3377070A4 (en) | 2015-11-20 | 2019-07-10 | Sage Therapeutics, Inc. | COMPOUNDS AND METHOD FOR THEIR USE |
| US20200306265A1 (en) | 2016-03-08 | 2020-10-01 | Sage Therapeutics, Inc. | Neuroactive steroids, compositions, and uses thereof |
| US10226550B2 (en) | 2016-03-11 | 2019-03-12 | Brigham Young University | Cationic steroidal antimicrobial compositions for the treatment of dermal tissue |
| AU2017297375B2 (en) | 2016-07-11 | 2022-09-15 | Sage Therapeutics, Inc. | C17, C20, and C21 substituted neuroactive steroids and their methods of use |
| WO2018013615A1 (en) | 2016-07-11 | 2018-01-18 | Sage Therapeutics, Inc. | C7, c12, and c16 substituted neuroactive steroids and their methods of use |
| MA46042A (fr) | 2016-08-23 | 2019-07-03 | Sage Therapeutics Inc | Stéroïde c21-n-pyrazolyle 3-disubstitué en 19-nor c3 cristallin |
| CN111065394B (zh) | 2017-08-31 | 2023-03-31 | 武田药品工业株式会社 | 中枢神经系统病症的治疗 |
-
2012
- 2012-10-12 JP JP2014535962A patent/JP2014528485A/ja not_active Withdrawn
- 2012-10-12 EP EP19169283.9A patent/EP3572417B1/en active Active
- 2012-10-12 CA CA2852057A patent/CA2852057C/en active Active
- 2012-10-12 CN CN201280060883.4A patent/CN104136452A/zh active Pending
- 2012-10-12 US US14/351,449 patent/US20150291654A1/en not_active Abandoned
- 2012-10-12 ES ES12781534T patent/ES2738526T3/es active Active
- 2012-10-12 CN CN201810869360.3A patent/CN108976272B/zh active Active
- 2012-10-12 AU AU2012323888A patent/AU2012323888A1/en not_active Abandoned
- 2012-10-12 CN CN202110494113.1A patent/CN113234114A/zh active Pending
- 2012-10-12 PT PT12781534T patent/PT2766380T/pt unknown
- 2012-10-12 EP EP12781534.8A patent/EP2766380B1/en active Active
- 2012-10-12 CA CA3152410A patent/CA3152410A1/en active Pending
- 2012-10-12 WO PCT/US2012/060136 patent/WO2013056181A1/en not_active Ceased
- 2012-10-12 CN CN202411226456.XA patent/CN119192266A/zh active Pending
-
2017
- 2017-07-26 AU AU2017208284A patent/AU2017208284B2/en active Active
- 2017-08-21 US US15/681,983 patent/US10435431B2/en active Active
- 2017-12-07 JP JP2017235371A patent/JP6745783B2/ja active Active
-
2019
- 2019-04-30 AU AU2019203046A patent/AU2019203046B2/en active Active
- 2019-08-22 US US16/548,248 patent/US20200223884A1/en not_active Abandoned
-
2020
- 2020-08-04 JP JP2020132282A patent/JP7096864B2/ja active Active
- 2020-10-22 US US17/077,025 patent/US20210040141A1/en not_active Abandoned
-
2021
- 2021-07-08 AU AU2021204782A patent/AU2021204782B2/en active Active
-
2022
- 2022-06-24 JP JP2022101881A patent/JP7617057B2/ja active Active
- 2022-10-19 US US17/969,105 patent/US20230287037A1/en not_active Abandoned
-
2023
- 2023-06-26 AU AU2023204015A patent/AU2023204015B2/en active Active
-
2025
- 2025-01-06 JP JP2025001804A patent/JP2025061026A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PT2766380T (pt) | Compostos de 19-nor pregnano 3,3-dissubstituídos, composições e seus usos | |
| IL269858A (en) | Pyridone and aza-pyridone compounds, pharmaceutical composition and kits comprising the same and uses thereof | |
| IL253870A0 (en) | Certain amino-pyrimidines, their assemblies, and methods of using them | |
| PL2753632T3 (pl) | Neuroaktywne steroidy, kompozycje i ich zastosowanie | |
| IL233154A (en) | Compounds, pharmaceuticals containing them and their uses | |
| PH12014501108A1 (en) | Anti-il-36r antibodies | |
| IL222465A0 (en) | Certain amino-pyridazines, compositions thereof, and methods for their use | |
| IL227815A0 (en) | Pyrrolopyrazine-spirocyclic piperidine amide compounds, and preparations containing them and their uses | |
| IL222738A0 (en) | Pharmaceutical emulsion composition comprising progestogen | |
| HUE041685T2 (hu) | 2,3,3,3-Tetrafluor-propént tartalmazó készítmény | |
| PT2431442T (pt) | Composição à base de 1,3,3,3-tetrafluoropropeno | |
| IL237625A0 (en) | Antibodies against m-cam, preparations containing them and their uses | |
| GB201218752D0 (en) | Mineral complex, compositions thereof, and methods of using the same | |
| PL2588556T3 (pl) | Kompozycja na bazie 2,3,3,3-tetrafluoropropenu | |
| IL226383B (en) | Antibodies against ccl20, preparations containing them and their uses | |
| IL235004A0 (en) | Antibodies against fgfr2, preparations containing them and their uses | |
| PL2619278T3 (pl) | Kompozycja na bazie 3,3,3-trifluoropropenu | |
| EP2755486A4 (en) | DISINFECTING COMPOSITIONS AND USES THEREOF | |
| IL222707B (en) | Steroid compounds of 16-chloro- and 16, 16-dichloro-(4-alpha, 4-beta)-17-beta-(2-oxo-2h-pyran-5-yl) and pharmaceutical preparations containing them | |
| IL232383B (en) | Antibodies against kdr, preparations containing them and their uses | |
| IL228403A0 (en) | Preparations containing anti-influenza antibodies and osetamivir and their uses | |
| HK40120913A (zh) | 3，3-二取代的19-去甲孕甾烷化合物、组合物、及其用途 | |
| EP2600958A4 (en) | COMPOSITIONS AND METHODS THEREFOR FOR SEPARATING EMULSIONS | |
| EP2544534A4 (en) | COMPOSITIONS, METHODS AND DEVICES USED IN THE TREATMENT OF DYSMENORRHEA | |
| TN2014000207A1 (en) | Anti il-36r antibodies |